These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 24636268)
1. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients with postoperative recurrence following platinum-based chemotherapy. Kaira K; Yamamoto N; Kenmotsu H; Murakami H; Ono A; Naito T; Endo M; Takahashi T Respir Investig; 2014 Mar; 52(2):121-8. PubMed ID: 24636268 [TBL] [Abstract][Full Text] [Related]
2. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556 [TBL] [Abstract][Full Text] [Related]
3. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701 [TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Lee JW; Na JO; Kang DY; Lee SY; Lee SM Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385 [TBL] [Abstract][Full Text] [Related]
5. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients. Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small cell lung cancer treated with induction chemotherapy. Lee HY; Choi WH; Yoo IR; Park JK; Sung SW; Kim YS; Kang JH Asia Pac J Clin Oncol; 2020 Feb; 16(1):70-74. PubMed ID: 31782256 [TBL] [Abstract][Full Text] [Related]
7. Influence of Body Mass Index on the Prognostic Value of Tumor ¹⁸F-FDG Uptake in Stage I Non-Small Cell Lung Cancer. Hyun SH; Lee KH; Choi JY; Kim BT; Kim J; Zo JI; Kim H; Kwon OJ; Ahn HK PLoS One; 2015; 10(12):e0145020. PubMed ID: 26684001 [TBL] [Abstract][Full Text] [Related]
8. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer? Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546 [TBL] [Abstract][Full Text] [Related]
9. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer. Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589 [TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value. Bengtsson T; Hicks RJ; Peterson A; Port RE J Nucl Med; 2012 Apr; 53(4):530-7. PubMed ID: 22414632 [TBL] [Abstract][Full Text] [Related]
12. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768 [TBL] [Abstract][Full Text] [Related]
13. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134 [TBL] [Abstract][Full Text] [Related]
14. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer. Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
16. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy. Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432 [TBL] [Abstract][Full Text] [Related]
19. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer. Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397 [TBL] [Abstract][Full Text] [Related]
20. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma. Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Kondo H; Nakajima T; Yamamoto N Lung Cancer; 2011 Feb; 71(2):144-50. PubMed ID: 20646779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]